Report: Intec To Sign $150M Agreement

April 13, 2015 | Intec Pharma is reportedly set to reach an agreement with a major pharmaceutical company worth $150 million, according to a “Globes” report. According to the terms of the reported agreement, Intec will develop its delayed release accordion pill for drugs entering the intestine. In addition, “Globes” reports that the agreement stipulates an additional $1 million for initial R&D and a possible rights agreement regarding the development and distribution of the drug. Intec Pharma was founded in 2000 and is headquartered in Jerusalem.